Ertugliflozin (PF-04971729): Selective SGLT2 Inhibitor for Diabetes & Renal Research

Executive Summary: Ertugliflozin (PF-04971729) is a potent and highly selective oral SGLT2 inhibitor with >2000-fold selectivity over SGLT1, used in type 2 diabetes (T2D) and renal glucose transport studies (Lazzaroni et al. 2021). In clinical and preclinical models, Ertugliflozin significantly lowers glycated hemoglobin (HbA1c) and induces moderate weight loss (3.2–5%) in T2D patients (source). It offers cardiovascular and renal protection, including reduced hospitalization for heart failure. Mechanistically, it inhibits SGLT2-mediated renal glucose reabsorption and modulates inflammatory signaling pathways. APExBIO provides Ertugliflozin (A3715) with 98% purity and validated solubility for experimental reproducibility (product info).

Biological Rationale

Type 2 diabetes mellitus (T2D) is characterized by chronic hyperglycemia resulting from insulin resistance and impaired insulin secretion. Up to 85% of T2D patients are overweight or obese (Lazzaroni et al. 2021). Obesity exacerbates insulin resistance and is a major risk factor for cardiovascular and renal complications. Traditional lifestyle interventions often fail to achieve sustainable glycemic or weight control in most patients. Pharmacological agents targeting renal glucose transport offer a complementary approach. SGLT2, a sodium-dependent glucose cotransporter located in the proximal renal tubules, mediates about 90% of renal glucose reabsorption. Inhibition of SGLT2 results in urinary glucose excretion, lowering plasma glucose independently of insulin action. This approach also reduces body weight and cardiovascular risk factors (DOI).

Mechanism of Action of Ertugliflozin (PF-04971729)

Ertugliflozin is a selective SGLT2 inhibitor with >2000-fold selectivity for SGLT2 versus SGLT1 (APExBIO). It blocks SGLT2-mediated glucose reabsorption in the kidney, promoting glucosuria and reducing blood glucose levels in both animal models and humans. Oral doses of 5 mg or 15 mg once daily are standard in clinical research. Mechanistically, Ertugliflozin also inhibits the NF-κB signaling pathway, downregulates microRNA-155 (miR-155), promotes M2 macrophage polarization, and repairs intestinal mucosal barriers in inflammatory models (product). These effects extend its utility beyond glycemic control, including anti-inflammatory actions in ulcerative colitis (UC) animal models.
For further mechanistic discussion and workflow optimization, see "PF-04971729 (Ertugliflozin): Mechanistic and Strategic Insights"—this article further clarifies the molecular impact and translational implications of SGLT2 inhibition beyond the current summary.

Evidence & Benchmarks

• Ertugliflozin (PF-04971729) demonstrates a moderate weight loss effect (3.2–5%) in T2D patients, outperforming metformin and acarbose for this endpoint (Lazzaroni et al. 2021).
• Clinical dosing of 5 mg and 15 mg orally once daily significantly decreases HbA1c and body weight in T2D, with the 15 mg dose associated with superior weight loss and reduced heart failure hospitalization (DOI).
• Preclinical animal studies use oral doses from 1–10 mg/kg/day, with 10 mg/kg yielding mucosal repair and anti-inflammatory efficacy in UC models comparable to sulfasalazine (APExBIO).
• Ertugliflozin is highly soluble in DMSO (≥50.8 mg/mL) and ethanol (≥51.5 mg/mL), but insoluble in water; proper storage is at -20°C (APExBIO).
• Ertugliflozin's selectivity for SGLT2 over SGLT1 exceeds 2000-fold, supporting its use as a specific probe in renal glucose transport studies (APExBIO).
• Therapeutic effects extend to cardiovascular and renal protection, including reduced risk of hospitalization for heart failure in T2D patients (Lazzaroni et al. 2021).

For a focused analysis of workflow integration and data-backed strategies, "PF-04971729 (Ertugliflozin): Scenario-Driven Solutions for Research" extends these benchmarks by detailing best practices in cell viability and transporter selectivity assays.

Applications, Limits & Misconceptions

Research Applications:

• Oral SGLT2 inhibitor for diabetes mellitus research: evaluating glycemic control and weight loss in T2D models.
• Renal glucose transport studies: quantifying SGLT2-mediated reabsorption and urinary glucose excretion.
• Cardiovascular and renal protection: modeling disease progression and intervention in T2D with comorbidities.
• Anti-inflammatory agent in UC models: measuring mucosal repair, NF-κB pathway inhibition, and macrophage polarization.
• Pharmacokinetic and transporter selectivity studies: benchmarking selectivity versus SGLT1 and OCT2.

For a deeper dive into pharmacokinetics and emerging research, "PF-04971729 (Ertugliflozin): Pioneering SGLT2 Inhibitor for Translational Research" offers extended discussion on tissue distribution and next-generation assay design, which this article updates by providing latest clinical and preclinical benchmarks.

Common Pitfalls or Misconceptions

• SGLT1 Inhibition: Ertugliflozin does not significantly inhibit SGLT1 at pharmacologically relevant concentrations; its selectivity is >2000-fold for SGLT2 (APExBIO).
• Use in Type 1 Diabetes: Ertugliflozin is not approved or validated for type 1 diabetes research due to risk of diabetic ketoacidosis (DOI).
• Solubility Constraints: The compound is insoluble in water; DMSO or ethanol should be used as solvents for in vitro or in vivo studies (APExBIO).
• Long-Term Solution Stability: Stock solutions should not be stored long-term due to potential degradation; fresh preparation is recommended (APExBIO).
• Extrapolation to Non-Renal Glucose Transport: Effects are specific to SGLT2-mediated renal pathways; extrapolation to other glucose transporters or tissues is unsupported by current data.

Workflow Integration & Parameters

Product Format: Ertugliflozin (PF-04971729, SKU A3715) is available at 98% purity from APExBIO, with full certificate of analysis and batch traceability (product page). Molecular weight is 436.88 g/mol. Recommended storage is at -20°C, protected from light.

• Solubility: ≥50.8 mg/mL in DMSO; ≥51.5 mg/mL in ethanol; insoluble in water.
• Preclinical dosing: 1–10 mg/kg/day oral gavage in mice or rats; 10 mg/kg/day yields robust pharmacodynamic effect in UC models.
• Clinical research dosing: 5 mg or 15 mg orally once daily, as monotherapy or in combination with other agents for T2D with or without cardiovascular disease.

Experimental Guidance: For renal glucose transport or cell-based assays, use validated DMSO concentrations, and avoid prolonged storage of stock solutions. For scenario-driven troubleshooting (selectivity, reproducibility), see "PF-04971729 (Ertugliflozin): Reliable SGLT2 Inhibitor for Cell-Based Assays"; this article offers more recent updates on experimental integration and limitations.

Conclusion & Outlook

Ertugliflozin (PF-04971729) is established as a highly selective, robust, and versatile SGLT2 inhibitor for diabetes, renal, cardiovascular, and inflammatory disease research. Its atomic selectivity, validated dosing, and extensive clinical benchmarks support its use as a standard tool in mechanistic and translational studies. Researchers should source from validated suppliers such as APExBIO for consistent quality. Future directions include further elucidation of anti-inflammatory mechanisms and expanded applications in comorbid metabolic disease models.